Evidence map›Paper›PMID 33634992›Full record

ArticleClinical and translational medicine2021

SARS-CoV-2-related IFITM3 in immune dysfunction and tumor microenvironment: An integrative analysis in pan-cancers.

Xue-Ping Li, Xin Huang, Yan-Mei Qin, Guo-Yan Wu, Cheng-Cai Liang, Yu-Jun Dai, Wei-Na Zhang

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Xue-Ping LiDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xin HuangState Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.ORCID 0000-0002-0359-7290
Yan-Mei QinDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China.
Guo-Yan WuDepartment of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cheng-Cai LiangState Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yu-Jun DaiDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0002-8528-182X
Wei-Na ZhangDepartment of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Sun Yat-sen University · CNGuangzhou Women and Children Medical Center · CNNantong University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

A549 CellsCOVID-19FemaleHumansMaleMembrane ProteinsNeoplasmsRNA-Binding ProteinsSARS-CoV-2Tumor MicroenvironmentIFITM3 protein, humanMembrane ProteinsRNA-Binding Proteins

Identifiers

PMID33634992
PMCPMC7901722
OpenAlexW3131558554

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.